Rapid-acting insulin formulation comprising an oligosaccharide

Patent metadata

Field	Value
Publication number	US-9492467-B2
Application number	US-201414581239-A
Country	US
Kind code	B2
Filing date	Dec 23, 2014
Priority date	Nov 2, 2011
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

A composition in aqueous solution, including an insulin and at least one oligosaccharide whose average degree of polymerization is between 3 and 13 and whose polydispersity index PDI is above 1.0, the oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable.

First claim

What is claimed is:

1. A composition in aqueous solution, comprising insulin and at least one oligosaccharide whose average degree of polymerization is from 3 to 6 and whose polydispersity index (PDI) is above 1.0, said oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable.

2. The composition as claimed in claim 1 , wherein the composition further comprises at least one polyanionic compound.

3. The composition as claimed in claim 2 , wherein the polyanionic compound is selected from the group consisting of anionic molecules; anionic polymers; and compounds consisting of a skeleton formed from a discrete number p, wherein 1≦p≦8, of identical or different saccharide units, bound by identical or different glycosidic bonds that are naturally carriers of carboxyl groups or are substituted with carboxyl groups.

4. The composition as claimed in claim 1 , wherein the composition is free of polyanionic compound.

5. The composition as claimed in claim 1 , wherein the insulin is a human insulin.

6. The composition as claimed in claim 1 , wherein the insulin is an insulin analog.

7. The composition as claimed in claim 6 , wherein the insulin analog is selected from the group consisting of insulin lispro, insulin aspart and insulin glulisine.

8. The composition as claimed in claim 6 , wherein the insulin analog is insulin lispro.

9. The composition as claimed in claim 1 , wherein the oligosaccharide/insulin weight ratio is between 0.4 and 10.

10. The composition as claimed in claim 1 , wherein the oligosaccharide is selected from the oligosaccharides of the following general formula I:

in which:
the oligosaccharide is a dextran,
F results from the coupling between linker arm R and an —OH of the oligosaccharide and being either an ester, carbamate or ether,
R is a chain comprising between 1 and 15 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, and having at least one carboxyl group,
Phe is a residue of a phenylalanine derivative, of absolute configuration L or D, produced from coupling between the amine of the phenylalanine derivative and at least one acid carried by group R prior to attachment to Phe,
n represents the mole fraction of R substituted with Phe and is between 0.3 and 0.9,
i represents the average mole fraction of groups F—R-[Phe]n borne per saccharide unit and is between 0.5 and 2.5,
when R is not substituted with Phe, the acid or acids of group R are carboxylates with an alkaline cation.

11. The composition as claimed in claim 10 , wherein the composition is free of polyanionic compound.

12. A pharmaceutical formulation comprising a composition as claimed in claim 1 .

13. The pharmaceutical formulation as claimed in claim 12 , wherein the concentration of insulin is between 240 and 3000 μM or 40 to 500 IU/mL.

14. The pharmaceutical formulation as claimed in claim 12 , wherein the concentration of insulin is between 600 and 1200 μM or 100 and 200 IU/mL.

15. A method for preparing a pharmaceutical formulation of insulin, comprising the step of mixing the insulin with at least one oligosaccharide whose average degree of polymerization is from 3 to 6 and whose polydispersity index (PDI) is above 1.0, wherein the method optionally comprises a step of adding a polyanionic compound to the formulation, and wherein after administration, the formulation accelerates the passage of insulin into the blood and reduces glycemia more rapidly relative to an oligosaccharide-free formulation.

16. The method as claimed in claim 15 , wherein the oligosaccharide is selected from the oligosaccharides of the following general formula I:

in which:
the oligosaccharide is a dextran,
F results from the coupling between linkage R and an —OH of the oligosaccharide and being either an ester, carbamate or ether,
R is a chain comprising between 1 and 15 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, and having at least one carboxyl group,
Phe is a residue of a phenylalanine derivative, of absolute configuration L or D, produced from coupling between the amine of the phenylalanine derivative and at least one acid carried by group R prior to attachment to Phe,
n represents the mole fraction of R substituted with Phe and is between 0.3 and 0.9,
i represents the average mole fraction of groups F—R-[Phe]n borne per saccharide unit and is between 0.5 and 2.5,
when R is not substituted with Phe, the acid or acids of group R are carboxylates with an alkaline cation.

17. The method as claimed in claim 15 , wherein the polyanionic compound is selected from the group consisting of anionic molecules; anionic polymers; and compounds consisting of a skeleton formed from a discrete number p, wherein 1≦p≦8, of identical or different saccharide units, bound by identical or different glycosidic bonds that are naturally carriers of carboxyl groups or are substituted with carboxyl groups.

18. The method as claimed in claim 15 , wherein the method does not comprise the step of adding a polyanionic compound.

19. A method of preparing a formulation of human insulin having an insulin concentration between 240 and 3000 μM or 40 and 500 IU/mL, comprising the step of mixing the human insulin with at least one oligosaccharide whose average degree of polymerization is from 3 to 6 and whose polydispersity index (PDI) is above 1.0, wherein the method optionally comprises a step of adding at least one polyanionic compound to the formulation, and wherein onset of action of the formulation in humans is less than that of the reference formulation at the same insulin concentration in the absence of oligosaccharide.

20. The method as claimed in claim 19 , wherein the method further comprises the step of adding at least one polyanionic compound to said formulation.

21. The method as claimed in claim 20 , wherein the polyanionic compound is selected from the group consisting of anionic molecules; anionic polymers; and compounds consisting of a skeleton formed from a discrete number p, wherein 1≦p≦8, of identical or different saccharide units, bound by identical or different glycosidic bonds that are naturally carriers of carboxyl groups or are substituted with carboxyl groups.

22. The method as claimed in claim 19 , wherein the method does not comprise the step of adding a polyanionic compound to said formulation.

23. The method as claimed in claim 19 , wherein the oligosaccharide is selected from the oligosaccharides of the following general formula I:

in which:
the oligosaccharide is a dextran,
F results from the coupling between linkage R and an —OH of the oligosaccharide and being either an ester, carbamate or ether,
R is a chain comprising between 1 and 15 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, and having at least one carboxyl group,
Phe is a residue of a phenylalanine derivative, of absolute configuration L or D, produced from coupling between the amine of the phenylalanine derivative and at least one acid carried by group R prior to attachment to Phe,
n represents the mole fraction

Assignees

• Adocia

Inventors

• Soula Olivier
• Soula Rémi
• SOULA GéRARD

Classifications

• A61K31/702 Primary

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title

• A61K38/28

  Insulins · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/61

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title